Literature DB >> 29760598

Predictors of chemoradiation related febrile neutropenia prophylaxis in older adults - Experience from a limited resource setting.

Aparna Gangopadhyay1.   

Abstract

AIM: To identify risk factors that lower efficacy of antibiotic prophylaxis of febrile neutropenia among older patients on chemoradiation.
BACKGROUND: Audit of institutional data showed that older adults are at higher risk of febrile neutropenia during chemoradiation. In limited resource settings widespread use of Granulocyte-Colony Stimulating Factor (G-CSF) is not economically feasible and antibiotics are used commonly. Despite compliance with antibiotics, prophylaxis is inadequate in many patients owing to patient and tumor related factors.
MATERIALS AND METHODS: Data from records of 219 older patients receiving antibiotic prophylaxis during chemoradiation were studied. Baseline assessment data and predisposing factors for febrile neutropenia were recorded. All patients received prophylactic fluoroquinolones. Incidence of febrile neutropenia and association with predisposing factors at baseline was analyzed by multiple logistic regression.
RESULTS: 38.4% developed febrile neutropenia despite compliance. Multiple logistic regression revealed geriatric assessment (G8) score and tumor stage to be significant predictors of febrile neutropenia while on antibiotics (p < 0.0001). Odds ratios for two significant predictors G8 score and tumor stage, respectively, were 2.9 (95% CI 1.8036-4.6815) and 2.7 (95% CI 1.7501-4.1318). Correlation between these two significant predictors was found to be low in our cohort (Spearman's coefficient of rank correlation (rho) - 0.431, p < 0.0001).
CONCLUSION: G8 score and tumor burden are significant predictors of efficacy of antibiotic prophylaxis among older adults receiving chemoradiation. In older patients having poor G8 scores and advanced tumors, antibiotic prophylaxis is unsuitable. Interestingly, co-morbidities and poor performance status did not impact efficacy of antibiotic prophylaxis among our elderly patients.

Entities:  

Keywords:  Antibiotic prophylaxis; Chemotherapy; Febrile neutropenia; Fluoroquinolones; Limited resource practice; Oncology in older adults

Year:  2018        PMID: 29760598      PMCID: PMC5948322          DOI: 10.1016/j.rpor.2018.02.004

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  10 in total

1.  Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

Authors:  J de Naurois; I Novitzky-Basso; M J Gill; F Marti Marti; M H Cullen; F Roila
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.

Authors:  Eric James Bow
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

3.  2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Authors:  M S Aapro; J Bohlius; D A Cameron; Lissandra Dal Lago; J Peter Donnelly; N Kearney; G H Lyman; R Pettengell; V C Tjan-Heijnen; J Walewski; Damien C Weber; C Zielinski
Journal:  Eur J Cancer       Date:  2010-11-20       Impact factor: 9.162

4.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.

Authors:  W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

5.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

6.  Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.

Authors:  Giampaolo Bucaneve; Alessandra Micozzi; Francesco Menichetti; Pietro Martino; M Stella Dionisi; Giovanni Martinelli; Bernardino Allione; Domenico D'Antonio; Maurizio Buelli; A Maria Nosari; Daniela Cilloni; Eliana Zuffa; Renato Cantaffa; Giorgina Specchia; Sergio Amadori; Francesco Fabbiano; Giorgio Lambertenghi Deliliers; Francesco Lauria; Robin Foà; Albano Del Favero
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

7.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 8.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  A Gafter-Gvili; A Fraser; M Paul; M van de Wetering; L Kremer; L Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 9.  Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.

Authors:  Gary H Lyman; Esteban Abella; Ruth Pettengell
Journal:  Crit Rev Oncol Hematol       Date:  2013-12-12       Impact factor: 6.312

10.  Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.

Authors:  Christopher R Flowers; Jerome Seidenfeld; Eric J Bow; Clare Karten; Charise Gleason; Douglas K Hawley; Nicole M Kuderer; Amelia A Langston; Kieren A Marr; Kenneth V I Rolston; Scott D Ramsey
Journal:  J Clin Oncol       Date:  2013-01-14       Impact factor: 44.544

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.